Wed, Jul 9, 2014, 11:06 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Peregrine Pharmaceuticals, Inc. Message Board

jay_scott27 37 posts  |  Last Activity: Jul 8, 2014 4:45 PM Member since: Apr 25, 2003
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • jay_scott27 by jay_scott27 Jul 8, 2014 4:45 PM Flag

    Six 21-day cycles of docetaxel plus weekly bavituximab. Patients who have not experienced disease progression will continue to receive bavituximab weekly until progression.

    They started in Dec 13, Six 21 day cycles equals 126 days or 4.2 Months So something should have been known in April. I believe that people haven't reached progression yet. We know from previous trials Bavi was extended life 4.2 months. So I would look for something in August or September as a preliminary. Final results are completed until 12/16. :(

    Sentiment: Strong Buy

  • jay_scott27 by jay_scott27 Jul 7, 2014 4:37 PM Flag

    Ok, I reported that e-trade had earnings listed for 7/7/14. I have been with etrade for over 14 years, They have never been wrong on earnings dates. I surmise that Peregrine needed another week to get their Facts in order. Collaboration? Still a Monday That's a good thing anyway you look at it.

    Sentiment: Strong Buy

  • Reply to

    Inst. ownership

    by mansman1100 Jul 3, 2014 9:42 AM
    jay_scott27 jay_scott27 Jul 3, 2014 12:22 PM Flag

    Actually it increased .5 of a percentage point overall, Institutional versus individual.

  • jay_scott27 jay_scott27 Jul 3, 2014 12:14 PM Flag

    I concur.

    Sentiment: Strong Buy

  • jay_scott27 jay_scott27 Jul 3, 2014 12:10 PM Flag

    1 year and two months to be exact. But that's not to say they won't disclose an agreement with a big Pharma.

    Sentiment: Strong Buy

  • Reply to

    PPHM Reporting

    by jay_scott27 Jun 30, 2014 9:39 AM
    jay_scott27 jay_scott27 Jul 3, 2014 10:10 AM Flag

    Earnings aren't significant, It's that they are reporting on a Monday, There must be good news to go along with earnings, Like a collaboration agreement.

    Sentiment: Strong Buy

  • Reply to

    PPHM Reporting

    by jay_scott27 Jun 30, 2014 9:39 AM
    jay_scott27 jay_scott27 Jul 1, 2014 9:15 PM Flag

    It's reported on my etrade account.

    Sentiment: Strong Buy

  • jay_scott27 by jay_scott27 Jul 1, 2014 12:32 PM Flag

    Anyone notice all of the insider buying over the last month?

    Sentiment: Strong Buy

  • jay_scott27 by jay_scott27 Jun 30, 2014 11:23 AM Flag

    You're not buying a company, You're buying a camera, Everyone and his brother will have their own in 6 months. Sell

    Sentiment: Strong Sell

  • jay_scott27 by jay_scott27 Jun 30, 2014 9:39 AM Flag

    PPHM will be reporting earnings on 7/7/14 That's a Monday folks. They never report on Mondays because earnings are always mediocre. Can only mean some type of good news. Volume has been up 3 days in a row. The real good news is still a year out.

    Sentiment: Strong Buy

  • jay_scott27 by jay_scott27 Jun 2, 2014 2:07 PM Flag

    Boston, MA 04/08/2014 (wallstreetpr) - Peregrine Pharmaceuticals (NASDAQ:PPHM) has introduced monoclonal antibodies for the diagnosis and treatment of cancerous cells present in the body. The U.S. based bio pharmaceutical company has reported that this very invention will help in opening a new horizon in the medical science.

    Announcement of the 3-abstracts of the company:

    The company has scheduled a poster presentation in order to present the 3-abstracts on the upcoming 105th annual meeting of AACR (Ameriacan Association for cancer Research). The presentation meet will be held from April 5 to April 9, 2014. The paper presentation venue has been selected as San Diego, California.

    Brief overview of the 3-Abstract details:

    The detailed presentation on the abstract number-639, LB-262 and 4978 will take place on the San Diego venue, explaining the survival and eradication of a small cell cancer and the antibody to check tumor growth. Panel of 14 members will be present there to judge the scenario.

    Peregrine Pharmaceuticals (NASDAQ:PPHM) latest updates:

    On April 7, 2014 Peregrine Pharmaceuticals (NASDAQ:PPHM)’s share went up by 6.53% and reached the value of $1.96. The latest announcement on the company stating the abstracts on the cancerous cell detection, analysis and resolution has gone in favor of the company’s reputation. An investigational immunotherapy, Bavituximab is being evaluated presently in NSCLC (Non Small Cell Lung Cancer).

    These impressive studies show a survival development on lung cancer treatment and reduction. After this sensational quote, Dr. Jeff T. Hutchins vice president of Peregrine Pharmaceuticals (NASDAQ:PPHM) demonstrated the considerable remedies of bavituximab activity.

    Treatment effect on the specimen:

    The study conducted on rats has come up with some amazing facts. Rats were injected twice on 3×12 Gy radiations only or 3×12 Gy combined with 2aG4. The latter has been considered with 67% success rate on 100% survival of the creatures after the 184 days of application. On the flip side, the success rate goes down. Now, it’s time to wait and see how much effective it is while applying on human cancerous cells!!

    Sentiment: Strong Buy

  • Reply to

    ASCO

    by jay_scott27 May 29, 2014 3:44 PM
    jay_scott27 jay_scott27 May 30, 2014 9:59 AM Flag

    You're a complete idiot that thinks everyone is out to get you. It is what it is dumb #$%$ . I know about all the trials and test results, I wouldn't be here if I didn't think the company was going to make me rich. Get your head out of the sand, And start acting civil maybe more people would take you serious. You think all these people on here have nothing better to do then to create conspiracy theories? Your nuts.

    Sentiment: Strong Buy

  • jay_scott27 jay_scott27 May 30, 2014 9:42 AM Flag

    Maybe that's why Chris Keenan told me that no news about trials would be discussed . Only trial design, what every that's suppose to mean.

    Sentiment: Strong Buy

  • Reply to

    ASCO

    by jay_scott27 May 29, 2014 3:44 PM
    jay_scott27 jay_scott27 May 30, 2014 9:28 AM Flag

    First of all what would be the reason for me to lie? And yes Chris Keenan did tell me that, so I take him on his word. And don't tell me he didn't I don't want to put you on ignore like the other board idiot.I've been here over 12 years. Sometimes you make a lot of sense, today you sound like an idiot

    Sentiment: Strong Buy

  • Reply to

    ASCO

    by jay_scott27 May 29, 2014 3:44 PM
    jay_scott27 jay_scott27 May 30, 2014 9:09 AM Flag

    I hope your right, I have been here for over 10 years.

    Sentiment: Strong Buy

  • Reply to

    ASCO

    by jay_scott27 May 29, 2014 3:44 PM
    jay_scott27 jay_scott27 May 30, 2014 9:07 AM Flag

    A guy name Chris Keenan called me back and told me, No trial data will be released for 1 1/2 to 2 years. I thought it was odd also. Sit and wait as usual .

    Sentiment: Strong Buy

  • jay_scott27 by jay_scott27 May 29, 2014 7:00 PM Flag

    53.50 tomorrow

    Sentiment: Strong Buy

  • Reply to

    ASCO

    by jay_scott27 May 29, 2014 3:44 PM
    jay_scott27 jay_scott27 May 29, 2014 3:45 PM Flag

    Of course I already knew we were still 2 years out.

    Sentiment: Strong Buy

  • jay_scott27 by jay_scott27 May 29, 2014 3:44 PM Flag

    They will be there explaining trial design, No data for a year and a half. Just talked to them.

    Sentiment: Strong Buy

  • jay_scott27 by jay_scott27 May 28, 2014 4:20 PM Flag

    I see Cramer and the boys are positioning their friends so that they can get in cheap. They use the statistic's to prove their point, Knowing full well what the possibilities are. Stay the course.

    Sentiment: Strong Buy

PPHM
1.75+0.03(+1.74%)Jul 9 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.